GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response

Chéramy, Mikael (Linköping University, Department of Clinical and Experimental Medicine, Pediatrics) (Linköping University, Faculty of Health Sciences)

Skoglund, Camilla (Linköping University, Department of Clinical and Experimental Medicine, Pediatrics) (Linköping University, Faculty of Health Sciences)

Johansson, Ingela (Linköping University, Department of Medical and Health Sciences, Cardiology) (Linköping University, Faculty of Health Sciences) (Östergötlands Läns Landsting, Heart Centre, Department of Cardiology)

Ludvigsson, Johnny (Linköping University, Department of Clinical and Experimental Medicine, Pediatrics) (Linköping University, Faculty of Health Sciences) (Östergötlands Läns Landsting, Centre of Paediatrics and Gynecology and Obstetrics, Department of Paediatrics in Linköping)

Hampe, Christiane S ( University of Washington)

Casas, Rosaura (Linköping University, Department of Clinical and Experimental Medicine, Pediatrics) (Linköping University, Faculty of Health Sciences)

Title:

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response

Department:

Östergötlands Läns Landsting, Centre of Paediatrics and Gynecology and Obstetrics, Department of Paediatrics in Linköping

Linköping University, Faculty of Health Sciences

Linköping University, Department of Medical and Health Sciences, Cardiology

Östergötlands Läns Landsting, Heart Centre, Department of Cardiology

Linköping University, Department of Clinical and Experimental Medicine, Pediatrics

Publication type:

Article in journal (Refereed)

Language:

English

Publisher: Elsevier Science B.V., Amsterdam

Status:

Published

In:

Clinical Immunology(ISSN 1521-6616)(EISSN 1521-7035)

Volume:

137

Issue:

Pages:

31-40

Year of publ.:

2010

URI:

urn:nbn:se:liu:diva-60511

Permanent link:

http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-60511

DOI:

10.1016/j.clim.2010.06.001

ISI:

000282204900005

Subject category:

Medical and Health Sciences

SVEP category:

MEDICINE

Keywords(en) :

Immunotherapy, GAD(65), GAD-alum, GADA, Type 1 diabetes, T1D, IgG, IgG subclass

Abstract(en) :

We have previously shown that two injections of 20 mu g GAD-alum to recent onset type 1 diabetic children induced GADA levels in parallel to preservation of insulin secretion. Here we investigated if boosted GADA induced changes in IgG1, 2, 3 and 4 subclass distributions or affected GAD(65) enzyme activity. We further studied the specific effect of GAD-alum through analyses of IA-2A, tetanus toxoid and total IgE antibodies. Serum from children receiving GAD alum or placebo was collected pre-treatment and after 3, 9, 15 and 21 months. At 3 months a reduced percentage of IgG1 and increased IgG3/IgG4 were detected in GAD-alum treated. Further, IA-2A, IgE and tetanus toxoid antibodies, as well as GAD(65) enzyme activity, were unaffected confirming the specific effect of treatment. In the GAD-alum group, higher pretreatment GADA were associated to more pronounced C-peptide preservation. The induced IgG3/IgG4 and reduced IgG1 suggest a Th2 deviation of the immune response.

Note:

Original Publication: Mikael Chéramy, Camilla Skoglund, Ingela Johansson, Johnny Ludvigsson, Christiane S Hampe and Rosaura Casas, GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response, 2010, CLINICAL IMMUNOLOGY, (137), 1, 31-40. http://dx.doi.org/10.1016/j.clim.2010.06.001 Copyright: Elsevier Science B.V., Amsterdam http://www.elsevier.com/

In thesis:

Skoglund, Camilla. Autoantibodies related to type 1 diabetes in children. 2011.

Chéramy, Mikael. Characteristics of GADA in Type 1 Diabetes following Immunomodulation with GAD₆₅. 2012.

Available from:

2010-10-15

Created:

2010-10-15

Last updated:

2012-10-24

Statistics:

83 hits

FILE INFORMATION